tolerability of the preservative-free (PF) fixed combination (FC) of tafluprost 0.0015% and timolol 0.5% (once daily) were compared to those of the individual components (PF tafluprost 0.0015% once daily and PF timolol 0.5% twice daily) in patients with open-angle glaucoma or ocular hypertension inadequately controlled on prior timolol or prostaglandin monotherapy for 6 months. Methods: A stratified, double-masked, randomized, multicenter phase III study was conducted. A total of 189 prior timolol users were randomized within the timolol stratum (TS) to receive either FC (n = 95) or timolol 0.5% (TIM; n = 94). Furthermore, a total of 375 prior prostaglandin analog (PGA) users were randomized within the prostaglandin stratum (PS) to receive either FC (n = 188) or tafluprost 0.0015% (TAF; n = 187). To be eligible for participation in the study, the patients were required to have an intraocular pressure (IOP)
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INTRODUCTION
The medical treatment of ocular hypertension and glaucoma is focused on reducing intraocular pressure (IOP) to reach and maintain the individual target IOP. However, for many patients, a single medication is not sufficient in this respect [1, 2] . If the target IOP cannot be achieved using a monotherapy, a combination of drugs with different mechanisms of action is recommended [3] . In recent years, the use of fixed combination (FC) glaucoma medications in patients with glaucoma or ocular hypertension has substantially increased. Fixed combinations contain two medications in a single bottle, which may be more convenient for the patient because fewer instillations and bottles are used, and thus likely improves compliance and adherence because of the simpler treatment regimen [4] . Multiple topical therapies may also be associated with a higher incidence of side effects [5] . Increased exposure to preservatives may have untoward effects on the ocular surface and may lead to a higher incidence of ocular signs and symptoms, and poor compliance [4, [6] [7] [8] . Benzalkonium chloride (BAK) is the most widely used preservative in IOP-lowering ophthalmic preparations.
However, it has been demonstrated in a variety of experimental and clinical studies to be pro-apoptotic and pro-inflammatory, to damage tear film layer, corneal epithelium and corneal nerves, and has a negative impact on the number of conjunctival goblet cells [9] [10] [11] [12] [13] . Ocular surface disease (OSD) and dry eye syndrome are frequently detected in patients treated with preserved glaucoma medications [14, 15] . It has been shown that OSD is related to the number of preserved eye drops used, the prolonged use of preserved medication and the total benzalkonium chloride (BAK) exposure [13] [14] [15] [16] .
The use of preservative-free (PF) formulations may avoid these negative effects of BAK [17] [18] [19] [20] [21] [22] .
PGA/timolol FCs are frequently used in glaucoma management. Both active ingredients of these fixed combinations have a different mode of action [3] . These fixed combinations provide an IOP reduction of approximately 30-37% and have to be instilled only once daily [23, 24] . The additivity and safety of tafluprost and timolol administered in a non-fixed combination (NFC) have been demonstrated in two randomized, double-masked, parallel-group, multicenter clinical studies [25, 26] . Thus, PF prostaglandin/timolol FC for the treatment of patients with glaucoma and ocular hypertension may have potential benefits for patients using fixed combinations of a prostaglandin analog and timolol.
The present study in patients with openangle glaucoma or ocular hypertension was designed to compare the IOP-lowering efficacy, safety and tolerability of the PF FC of tafluprost 0.0015% (TAF)/timolol 0.5% (TIM) ophthalmic solution to those of its individual components, namely, PF tafluprost 0.0015% and PF timolol 0.5%. 
METHODS

Study Design
Study Visits and Treatment
The study visits included screening, end-of-runin, baseline, 2 and 6 weeks, 3 and 6 months, and post-study ( Fig. 1 (Fig. 2) . Unilateral dosing of the study medication was also allowed when the contralateral eye required no treatment. All study medications were packed in identical single-dose containers and pouches for masking.
Efficacy Variables
Diurnal IOP measurements were made by calibrated Goldmann applanation tonometry 
Safety and Tolerability
The analysis of the safety and tolerability data was based on all the patients who received at least one dose of the respective study medication and had a subsequent safety measurement. Ocular and non-ocular adverse events (AEs) were recorded at each visit. Slit lamp examinations were conducted at each visit and the findings were graded on a scale from 0 to 3 (0: normal; 1: mild; 2: moderate; 3:
severe). Central corneal thickness (CCT) was measured at screening and at month 6 by ultrasound pachymetry. The severity of conjunctival hyperemia was assessed from baseline through month 6 using a set of reference photographs (redness grading) and a 5-point scale (0: none; 1: mild; 2: moderate; 3:
severe; 4: very severe). Ophthalmoscopic examinations were conducted via dilated pupil at screening and at months 3 and 6, and included the evaluation of vitreous, retina, and optic nerve head. Visual field testing was performed at screening and post-study. Drop discomfort was evaluated at weeks 2 and 6 and months 3 and 6 on a 4-point scale (0: none, 1:
mild, 2: moderate, 3: severe). Resting blood pressure and heart rate were measured twice during the day at 8:00 a.m. and 10:00 a.m. from baseline visit to month 6. Fig. 1 An overview of scheduled study visits for both prostaglandin stratum and timolol stratum. PGA prostaglandin analog, PS prostaglandin stratum, TS timolol stratum sizes provided the power of 90% based on differences of 2.0 mmHg for the TS and 1.5 mm Hg for the PS, a standard deviation (SD) of 4.0 mmHg for change in IOP, a drop-out rate of 20% and a two-sided 5% type I error. A smaller drop-out rate than anticipated was seen during the study, thus fewer patients could be randomized in the study without a loss in statistical power.
Statistical Methods
RESULTS
In total, 711 subjects were screened for the study. 
Efficacy in Prior Timolol Users (TS)
A clinically and statistically significant reduction of IOP from baseline was seen with FC preservative-free fixed combination tafluprost 0.0015%/timolol 0.5%, ITT intention to treat, SD standard deviation, TAF monotherapy preservative-free tafluprost 0.0015%, TIM monotherapy preservative-free timolol 0.5% both treatment regimens throughout the study, and low IOP levels were maintained in both treatment arms up to the 6-month visit. Timewise differences at all visits were clearly in favor of the FC: FC lowered IOP between 7.1 and 9.0 mmHg (within group p\0.001 at all time points, ITT dataset). In comparison, TIM 0.5% twice daily lowered IOP between 6.5 and 8.1 mmHg (within group p\0.001 at all time points, ITT dataset) (Fig. 3) . At month 3, the time-wise differences (FC-TIM) ranged on average from -1.50 to -0.85 mmHg (Fig. 4) , and the estimated average treatment difference (FC-TIM) from the primary RM ANCOVA model for the ITT LOCF dataset was -0.885 mmHg with a 95% CI from -1.745 to -0.024 mmHg (p = 0.044), thus superiority of FC over TIM was achieved ( Table 2 ). The sensitivity analysis without using the baseline IOP as a covariate (RM ANOVA) confirmed these results: the treatment difference at month 3 was 
Efficacy in Prior PGA users (PS)
A clinically and statistically significant reduction of IOP from baseline was seen with both treatment regimens throughout the study, and low IOP levels were maintained in both treatment arms up to 6 months. Time-wise differences at all visits were clearly in favor of the FC: FC lowered IOP between 8.2 and CI confidence interval, FC preservative-free fixed combination tafluprost 0.0015%/timolol 0.5%, IOP intraocular pressure, ITT intention to treat, LOCF last observation carried forward, PF preservative free, PS prostaglandin stratum, RM ANCOVA repeat measures analysis of the covariance, TAF monotherapy preservative-free tafluprost 0.0015%, TIM monotherapy preservative-free timolol 0.5%, TS timolol stratum Furthermore, all estimated time-wise treatment differences (FC-TAF) were clearly in favor of the FC, on average around 1.5 mmHg, and the favorable average difference was sustained up to 6 months (p\0.001; RM ANCOVA; ITT dataset).
Ocular and Non-ocular Adverse Events
In the TS, 94 related and non-related AEs (54 ocular, 40 non-ocular) were reported by 43 The most frequent ocular AEs (reported for more than 2 patients) are summarized in Table 3 for both strata. Most of the ocular AEs were graded as mild. Conjunctival/ocular hyperemia was the most frequent treatmentrelated AE in both strata. In the TS, treatmentrelated hyperemia was reported in 9 patients (9.5%) in the FC arm and for none in the TIM treatment arm. The evaluation of conjunctival redness in patients in the TIM arm also showed lower levels of redness, and a lower proportion of patients with low or no redness grading (Fig. 8a) .
In the PS, treatment-related hyperemia was reported in 9 patients (4.8%) in the FC arm and 6 patients (3.2%) in the TAF arm. In general, the severity of hyperemia was mild to moderate. In both strata, the mean severity of conjunctival hyperemia, evaluated by reference photographs, was highest at week 2 and showed a decreasing tendency during the course of the study (Fig. 8a and b ). There were no signs of treatment-related adverse events of the inner eye optical media and fundus or visual fields. No significant changes preservative-free fixed combination tafluprost 0.0015%/ timolol 0.5%, IOP intraocular pressure, TAF monotherapy preservative-free tafluprost 0.0015%, PS prostaglandin stratum prevalence rates between 45 and 60% [14, 15, 28] . Preservative-free glaucoma medications are generally better tolerated than preserved eye drops [18, 19] .
In the present study, we evaluated and compared the IOP-lowering efficacy, safety and tolerability of the PF FC of tafluprost 0.0015% and timolol 0.5% (administered once daily in the morning) to the individual PF components tafluprost 0.0015% (administered once daily in the morning) and timolol 0.5% (administered twice daily). It is well established that both PF tafluprost and timolol effectively reduce IOP as monotherapy [20, 21, 29, 30] , are additive in IOP reduction in concomitant use [25] and neither of these two substances requires BAK to enhance its IOP-lowering activity [20] [21] [22] [30] [31] [32] .
The results of this stratified, double-masked, Eye pruritus 4 0 FC preservative-free fixed combination tafluprost 0.0015%/timolol 0.5%, PGA prostaglandin analog, TAF monotherapy preservative-free tafluprost 0.0015%, TIM monotherapy preservative-free timolol 0.5% a The terms ' 'conjunctival hyperemia'' and ' 'ocular hyperemia' ' were used in parallel. Adverse events for this category were counted only once for each patient comparable range to those found for other preserved prostaglandin/timolol fixed combinations: Mean diurnal IOP decrease from baseline with a preserved fixed combination of latanoprost/timolol was 8.0 mmHg after 13 weeks with untreated baseline IOP levels that were comparable to the present study [33] . However, in this study design patients were treated with timolol 0.5% twice daily during a 2-week run-in period. In a study comparing a preserved fixed combination of bimatoprost/timolol with the individual components, mean diurnal IOP was decreased by 8.1 mmHg in the fixed combination treatment arm [34] . [35] .
The reduction of IOP in the FC treatment arms was superior to both individual components preservative-free fixed combination tafluprost 0.0015%/ timolol 0.5%, TAF monotherapy preservative-free tafluprost 0.0015%, TIM monotherapy preservative-free timolol 0.5%
analysis, it should be noted that it clearly influences the overall result ( confirmed these results. In the present study, the tafluprost/timolol FC was administered at 8:00 a.m. in the morning. In the PS, TAF was also instilled at 8:00 a.m., which allowed a fair comparison of the IOP-lowering effect of both treatment arms. Furthermore, timolol 0.5% was dosed twice daily in the TS. In general the evening administration had been slightly favoring the efficacy of prostaglandin analogs [23] . In a study conducted by Konstas [37] , morning versus evening dosing of a concomitant treatment of latanoprost 0.005%/ timolol 0.5% instilled once daily was compared. Overall, a trend for greater daytime IOP reduction with evening dosing was found, whereas morning dosing tended to provide lower night time pressures [37] . Furthermore, it could be shown for fixed combinations of travoprost and timolol, and bimatoprost and timolol, that evening dosing provided a better 24-h IOP control when compared to morning dosing [38, 39] .
The safety profile of the PF FC of tafluprost 0.0015% and timolol 0.5% was well in line with the known side effects of timolol and tafluprost.
Specifically, the hyperemia rates of the FC were very low in both strata: 4.8% and 9.5% for the PS and TS, respectively, and 6.4% over the two strata. The reason for the lower hyperemia rate in the PS compared to the TS may most likely be explained by the previous exposure of these patients to prostaglandin therapies. In turn, conjunctival hyperemia was reported for 22.7% of the patients at month 3 in the bimatoprost/ timolol fixed combination study [34] . Accordingly, hyperemia was reported for 14.1% of the patients treated with travoprost/ timolol preserved fixed combination [35] . These rates are considerably higher than those seen in the present study and suggest that the PF tafluprost/timolol FC may be better tolerated and an important treatment option for all patients who require an effective and safe combination therapy in clinical practice. 
APPENDIX
The following investigators participated in this multicenter clinical trial: The Preservative-free Tafluprost Fixed Combination Study Group:
